July 14, 2020Open Access

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Key Points

Key points are not available for this paper at this time.

Abstract

The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461).

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Jackson et al. (Tue,) studied this question.

synapsesocial.com/papers/69d6f19139aaaf0da5ab397d https://doi.org/https://doi.org/10.1056/nejmoa2022483

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Microneutralization Assay Titres Correlate with Protection against Seasonal Influenza H1N1 and H3N2 in Children2015 · 98 citations
2Rapid COVID-19 vaccine development2020 · 829 citations
3Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques2021 · 47 citations
4Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses2018 · 528 citations
5Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein2012 · 1,441 citations

Perguntar à IA

Bookmark

View Full Paper